Iterum Therapeutics plc (ITRM) 10-Year Financial Performance & Capital Metrics

ITRM • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more

Revenue $0
EBITDA -$18M +59.7%
Net Income -$25M +35.4%
EPS (Diluted) -1.26 +57.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -117.78% +28.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 52.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.5%

ROCE

10Y Avg-111.69%

5Y Avg-85.94%

3Y Avg-91.11%

Latest-94.11%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	508K	869K	37K	0	0	0	0	0
Revenue Growth %	-	-	0.71%	-0.96%	-1%	-	-	-	-
Cost of Goods Sold+	0	0	0	0	161K	2.1M	1.8M	1.75M	254K
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	508K	869K	37K	-161K	-2.1M	-1.8M	-1.75M	-254K
Gross Margin %	-	1%	1%	1%	-	-	-	-	-
Gross Profit Growth %	-	-	0.71%	-0.96%	-5.35%	-12.07%	0.14%	0.03%	0.85%
Operating Expenses+	13.36M	29.96M	77.43M	102.06M	31.96M	22.43M	28.58M	45.72M	18.44M
OpEx % of Revenue	-	58.98%	89.1%	2758.32%	-	-	-	-	-
Selling, General & Admin	3.26M	4.46M	8.78M	11.28M	11.05M	13.82M	12.77M	7.48M	7.98M
SG&A % of Revenue	-	8.79%	10.1%	304.97%	-	-	-	-	-
Research & Development	10.1M	25.5M	68.65M	90.77M	20.91M	8.61M	15.82M	38.24M	10.46M
R&D % of Revenue	-	50.19%	79%	2453.35%	-	-	-	-	-
Other Operating Expenses	8K	0	401K	196K	0	0	0	0	0
Operating Income+	-13.36M	-29.45M	-76.56M	-102.02M	-32.13M	-24.54M	-30.38M	-47.47M	-18.7M
Operating Margin %	-	-57.98%	-88.1%	-2757.32%	-	-	-	-	-
Operating Income Growth %	-	-1.2%	-1.6%	-0.33%	0.69%	0.24%	-0.24%	-0.56%	0.61%
EBITDA+	0	-29.39M	-76.42M	-101.87M	-31.96M	-22.43M	-28.58M	-45.72M	-18.41M
EBITDA Margin %	-	-57.85%	-87.94%	-2753.22%	-	-	-	-	-
EBITDA Growth %	-	-	-1.6%	-0.33%	0.69%	0.3%	-0.27%	-0.6%	0.6%
D&A (Non-Cash Add-back)	13.36M	65K	136K	152K	161K	2.1M	1.8M	1.75M	284K
EBIT	-13.35M	-29.45M	-76.16M	-101.83M	-36.17M	-85.31M	-41.77M	-36.33M	-22.01M
Net Interest Income+	0	277K	-426K	-861K	-15.09M	-5.55M	-2.36M	1.43M	0
Interest Income	0	277K	0	0	12.3K	4.53K	2.36K	1.43M	0
Interest Expense	0	0	426K	861K	15.1M	5.55M	2.36M	0	0
Other Income/Expense	8K	493K	-25K	-665K	-19.14M	-66.32M	-13.75M	9.71M	-5.84M
Pretax Income+	-13.35M	-28.96M	-76.58M	-102.69M	-51.26M	-90.86M	-44.13M	-37.76M	-24.53M
Pretax Margin %	-	-57.01%	-88.13%	-2775.3%	-	-	-	-	-
Income Tax+	113K	444K	472K	444K	743K	705K	301K	613K	240K
Effective Tax Rate %	1.01%	1.02%	1.01%	1%	1.01%	1.01%	1.01%	1.02%	1.01%
Net Income+	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Net Margin %	-	-57.89%	-88.67%	-2787.3%	-	-	-	-	-
Net Income Growth %	-	-1.18%	-1.62%	-0.34%	0.5%	-0.76%	0.51%	0.14%	0.35%
Net Income (Continuing)	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-26.59	-58.08	-98.32	-7.10	-32.49	-8.41	-3.63	-2.96	-1.26
EPS Growth %	-	-1.18%	-0.69%	0.93%	-3.58%	0.74%	0.57%	0.18%	0.57%
EPS (Basic)	-26.59	-58.08	-98.32	-7.10	-32.49	-8.41	-3.63	-2.96	-1.26
Diluted Shares Outstanding	13.96M	549.15K	631.57K	1.05M	24.01M	10.89M	12.24M	12.96M	19.7M
Basic Shares Outstanding	13.96M	549.15K	631.57K	1.05M	24.01M	10.89M	12.24M	12.96M	19.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.86M	44.17M	84.67M	9.38M	21.47M	83.27M	62.44M	25.6M	24.79M
Cash & Short-Term Investments	24.81M	39.22M	84.67M	4.83M	14.57M	81.34M	60.8M	23.93M	24.13M
Cash Only	24.81M	8.48M	44.55M	4.83M	14.57M	27.45M	21.09M	6.07M	24.13M
Short-Term Investments	0	30.73M	40M	0	0	53.9M	39.71M	17.86M	0
Accounts Receivable	245K	509K	721K	1.11M	865K	1.21M	513K	233K	66K
Days Sales Outstanding	-	365.72	302.84	10.96K	-	-	-	-	-
Inventory	0	0	-7.87M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	180K	959K	1.14M	5.24M	37K	35K	0	65K
Total Non-Current Assets+	1.05M	2.58M	13.2M	16.37M	11.32M	8.24M	4.39M	663K	19.81M
Property, Plant & Equipment	0	747K	700K	7.72M	5.68M	3.83M	1.84M	600K	23K
Fixed Asset Turnover	-	0.68x	1.24x	0.00x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	3.44M	1.72M	0	19.75M
Long-Term Investments	0	0	959K	60K	248K	64K	34K	0	0
Other Non-Current Assets	1.05M	1.84M	11.54M	8.6M	5.39M	912K	797K	63K	39K
Total Assets+	26.92M	46.76M	97.87M	25.75M	32.79M	91.51M	66.83M	26.26M	44.59M
Asset Turnover	-	0.01x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	-	0.74%	1.09%	-0.74%	0.27%	1.79%	-0.27%	-0.61%	0.7%
Total Current Liabilities+	4.22M	7.13M	12.22M	36.99M	41.7M	12.94M	9.06M	13.52M	17.61M
Accounts Payable	1.48M	3.15M	4.04M	15.49M	816K	878K	2.77M	5M	251K
Days Payables Outstanding	-	-	-	-	1.85K	152.31	562.51	1.04K	360.69
Short-Term Debt	0	0	1.02M	6.38M	7.06M	2.09M	332K	0	14.46M
Deferred Revenue (Current)	0	0	113K	0	0	0	0	0	0
Other Current Liabilities	1.95M	2.92M	5.24M	13.71M	32.75M	8.98M	3.99M	761K	240K
Current Ratio	6.13x	6.20x	6.93x	0.25x	0.51x	6.43x	6.89x	1.89x	1.41x
Quick Ratio	6.13x	6.20x	7.57x	0.25x	0.51x	6.43x	6.89x	1.89x	1.41x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	30K	137K	26.25M	15M	41.65M	28.33M	29.77M	19.14M	31.07M
Long-Term Debt	0	0	13.08M	7.63M	35.85M	24.9M	28.47M	18.96M	31.07M
Capital Lease Obligations	0	0	0	6.75M	5.17M	3.44M	1.3M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	30K	137K	951K	630K	630K	0	0	188K	0
Total Liabilities	4.25M	7.26M	26.25M	51.99M	83.35M	41.27M	38.83M	32.66M	48.68M
Total Debt+	0	0	13.08M	20.75M	48.08M	30.43M	30.1M	18.96M	45.53M
Net Debt	-24.81M	-8.48M	-31.47M	15.92M	33.52M	2.98M	9.01M	12.88M	21.41M
Debt / Equity	-	-	0.18x	-	-	0.61x	1.08x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-179.72x	-118.49x	-2.13x	-4.42x	-12.87x	-	-
Total Equity+	22.67M	39.49M	71.62M	-26.24M	-50.56M	50.23M	28M	-6.4M	-4.08M
Equity Growth %	-	0.74%	0.81%	-1.37%	-0.93%	1.99%	-0.44%	-1.23%	0.36%
Book Value per Share	1.62	71.92	113.40	-24.99	-2.11	4.61	2.29	-0.49	-0.21
Total Shareholders' Equity	22.67M	39.49M	71.62M	-26.24M	-50.56M	50.23M	28M	-6.4M	-4.08M
Common Stock	4K	4K	144K	149K	494K	1.83M	126K	135K	315K
Retained Earnings	-25.33M	-54.74M	-131.79M	-234.92M	-286.93M	-378.49M	-422.93M	-461.3M	-486.07M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-65K	-201K	0	0	0	-350K	1K	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.3M	-30.6M	-75.89M	-81.92M	-54.53M	-15.84M	-18.47M	-39.33M	-26.77M
Operating CF Margin %	-	-60.24%	-87.33%	-2214.11%	-	-	-	-	-
Operating CF Growth %	-	-1.71%	-1.48%	-0.08%	0.33%	0.71%	-0.17%	-1.13%	0.32%
Net Income	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Depreciation & Amortization	0	65K	136K	152K	161K	2.1M	1.8M	1.75M	284K
Stock-Based Compensation	348K	392K	1.29M	2.17M	2.76M	4.32M	22.11M	784K	363K
Deferred Taxes	0	44K	-701K	0	1.41M	61.6M	0	0	0
Other Non-Cash Items	-830K	-95K	2.04M	984K	17.71M	8.14M	-258K	-6.26M	10.09M
Working Capital Changes	1.82M	-1.6M	-1.6M	17.9M	-24.56M	-440K	2.31M	2.76M	-12.73M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	1.19M	1.67M	849K	11.45M	-14.67M	63K	1.9M	2.22M	-4.75M
Cash from Investing+	0	-31.59M	-8.66M	40.1M	-11K	-54.59M	13.96M	23.34M	18.21M
Capital Expenditures	0	-812K	-90K	-24K	-11K	-61K	-62K	-13K	-2K
CapEx % of Revenue	-	1.6%	0.1%	0.65%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-30.77K	-8.57K	0	0	-54.53K	0	0	0
Cash from Financing+	20.85M	45.87M	120.84M	2.06M	64.47M	83.13M	-1.82M	1.03M	26.69M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	60K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.3M	-31.42M	-75.98M	-81.95M	-54.54M	-15.9M	-18.54M	-39.34M	-26.77M
FCF Margin %	-	-61.84%	-87.43%	-2214.76%	-	-	-	-	-
FCF Growth %	-	-1.78%	-1.42%	-0.08%	0.33%	0.71%	-0.17%	-1.12%	0.32%
FCF per Share	-0.81	-57.21	-120.30	-78.04	-2.27	-1.46	-1.51	-3.04	-1.36
FCF Conversion (FCF/Net Income)	0.84x	1.04x	0.98x	0.79x	1.05x	0.17x	0.42x	1.02x	1.08x
Interest Paid	0	0	809K	1.4M	996K	416K	22K	0	0
Taxes Paid	130K	439K	352K	414K	120K	435K	821K	401K	220K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.4%	-94.61%	-138.69%	-454.48%	-	-182.28%	-113.59%	-355.35%	-
Return on Invested Capital (ROIC)	-	-153.05%	-161.38%	-512.94%	-	-101.76%	-50.51%	-163.72%	-117.78%
Gross Margin	-	100%	100%	100%	-	-	-	-	-
Net Margin	-	-5788.58%	-8867.2%	-278729.73%	-	-	-	-	-
Debt / Equity	-	-	0.18x	-	-	0.61x	1.08x	-	-
Interest Coverage	-	-	-179.72x	-118.49x	-2.13x	-4.42x	-12.87x	-	-
FCF Conversion	0.84x	1.04x	0.98x	0.79x	1.05x	0.17x	0.42x	1.02x	1.08x
Revenue Growth	-	-	71.06%	-95.74%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Iterum Therapeutics plc (ITRM) reported $0.4M in revenue for fiscal year 2024.

Iterum Therapeutics plc (ITRM) grew revenue by 0.0% over the past year. Growth has been modest.

Iterum Therapeutics plc (ITRM) reported a net loss of $27.0M for fiscal year 2024.

Dividend & Returns

Iterum Therapeutics plc (ITRM) had negative free cash flow of $19.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Iterum Therapeutics plc (ITRM) 10-Year Financial Performance & Capital Metrics

ITRM • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$18M +59.7%
Net Income -$25M +35.4%
EPS (Diluted) -1.26 +57.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -117.78% +28.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 52.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.5%

ROCE

10Y Avg-111.69%

5Y Avg-85.94%

3Y Avg-91.11%

Latest-94.11%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	508K	869K	37K	0	0	0	0	0
Revenue Growth %	-	-	0.71%	-0.96%	-1%	-	-	-	-
Cost of Goods Sold+	0	0	0	0	161K	2.1M	1.8M	1.75M	254K
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	508K	869K	37K	-161K	-2.1M	-1.8M	-1.75M	-254K
Gross Margin %	-	1%	1%	1%	-	-	-	-	-
Gross Profit Growth %	-	-	0.71%	-0.96%	-5.35%	-12.07%	0.14%	0.03%	0.85%
Operating Expenses+	13.36M	29.96M	77.43M	102.06M	31.96M	22.43M	28.58M	45.72M	18.44M
OpEx % of Revenue	-	58.98%	89.1%	2758.32%	-	-	-	-	-
Selling, General & Admin	3.26M	4.46M	8.78M	11.28M	11.05M	13.82M	12.77M	7.48M	7.98M
SG&A % of Revenue	-	8.79%	10.1%	304.97%	-	-	-	-	-
Research & Development	10.1M	25.5M	68.65M	90.77M	20.91M	8.61M	15.82M	38.24M	10.46M
R&D % of Revenue	-	50.19%	79%	2453.35%	-	-	-	-	-
Other Operating Expenses	8K	0	401K	196K	0	0	0	0	0
Operating Income+	-13.36M	-29.45M	-76.56M	-102.02M	-32.13M	-24.54M	-30.38M	-47.47M	-18.7M
Operating Margin %	-	-57.98%	-88.1%	-2757.32%	-	-	-	-	-
Operating Income Growth %	-	-1.2%	-1.6%	-0.33%	0.69%	0.24%	-0.24%	-0.56%	0.61%
EBITDA+	0	-29.39M	-76.42M	-101.87M	-31.96M	-22.43M	-28.58M	-45.72M	-18.41M
EBITDA Margin %	-	-57.85%	-87.94%	-2753.22%	-	-	-	-	-
EBITDA Growth %	-	-	-1.6%	-0.33%	0.69%	0.3%	-0.27%	-0.6%	0.6%
D&A (Non-Cash Add-back)	13.36M	65K	136K	152K	161K	2.1M	1.8M	1.75M	284K
EBIT	-13.35M	-29.45M	-76.16M	-101.83M	-36.17M	-85.31M	-41.77M	-36.33M	-22.01M
Net Interest Income+	0	277K	-426K	-861K	-15.09M	-5.55M	-2.36M	1.43M	0
Interest Income	0	277K	0	0	12.3K	4.53K	2.36K	1.43M	0
Interest Expense	0	0	426K	861K	15.1M	5.55M	2.36M	0	0
Other Income/Expense	8K	493K	-25K	-665K	-19.14M	-66.32M	-13.75M	9.71M	-5.84M
Pretax Income+	-13.35M	-28.96M	-76.58M	-102.69M	-51.26M	-90.86M	-44.13M	-37.76M	-24.53M
Pretax Margin %	-	-57.01%	-88.13%	-2775.3%	-	-	-	-	-
Income Tax+	113K	444K	472K	444K	743K	705K	301K	613K	240K
Effective Tax Rate %	1.01%	1.02%	1.01%	1%	1.01%	1.01%	1.01%	1.02%	1.01%
Net Income+	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Net Margin %	-	-57.89%	-88.67%	-2787.3%	-	-	-	-	-
Net Income Growth %	-	-1.18%	-1.62%	-0.34%	0.5%	-0.76%	0.51%	0.14%	0.35%
Net Income (Continuing)	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-26.59	-58.08	-98.32	-7.10	-32.49	-8.41	-3.63	-2.96	-1.26
EPS Growth %	-	-1.18%	-0.69%	0.93%	-3.58%	0.74%	0.57%	0.18%	0.57%
EPS (Basic)	-26.59	-58.08	-98.32	-7.10	-32.49	-8.41	-3.63	-2.96	-1.26
Diluted Shares Outstanding	13.96M	549.15K	631.57K	1.05M	24.01M	10.89M	12.24M	12.96M	19.7M
Basic Shares Outstanding	13.96M	549.15K	631.57K	1.05M	24.01M	10.89M	12.24M	12.96M	19.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.86M	44.17M	84.67M	9.38M	21.47M	83.27M	62.44M	25.6M	24.79M
Cash & Short-Term Investments	24.81M	39.22M	84.67M	4.83M	14.57M	81.34M	60.8M	23.93M	24.13M
Cash Only	24.81M	8.48M	44.55M	4.83M	14.57M	27.45M	21.09M	6.07M	24.13M
Short-Term Investments	0	30.73M	40M	0	0	53.9M	39.71M	17.86M	0
Accounts Receivable	245K	509K	721K	1.11M	865K	1.21M	513K	233K	66K
Days Sales Outstanding	-	365.72	302.84	10.96K	-	-	-	-	-
Inventory	0	0	-7.87M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	180K	959K	1.14M	5.24M	37K	35K	0	65K
Total Non-Current Assets+	1.05M	2.58M	13.2M	16.37M	11.32M	8.24M	4.39M	663K	19.81M
Property, Plant & Equipment	0	747K	700K	7.72M	5.68M	3.83M	1.84M	600K	23K
Fixed Asset Turnover	-	0.68x	1.24x	0.00x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	3.44M	1.72M	0	19.75M
Long-Term Investments	0	0	959K	60K	248K	64K	34K	0	0
Other Non-Current Assets	1.05M	1.84M	11.54M	8.6M	5.39M	912K	797K	63K	39K
Total Assets+	26.92M	46.76M	97.87M	25.75M	32.79M	91.51M	66.83M	26.26M	44.59M
Asset Turnover	-	0.01x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	-	0.74%	1.09%	-0.74%	0.27%	1.79%	-0.27%	-0.61%	0.7%
Total Current Liabilities+	4.22M	7.13M	12.22M	36.99M	41.7M	12.94M	9.06M	13.52M	17.61M
Accounts Payable	1.48M	3.15M	4.04M	15.49M	816K	878K	2.77M	5M	251K
Days Payables Outstanding	-	-	-	-	1.85K	152.31	562.51	1.04K	360.69
Short-Term Debt	0	0	1.02M	6.38M	7.06M	2.09M	332K	0	14.46M
Deferred Revenue (Current)	0	0	113K	0	0	0	0	0	0
Other Current Liabilities	1.95M	2.92M	5.24M	13.71M	32.75M	8.98M	3.99M	761K	240K
Current Ratio	6.13x	6.20x	6.93x	0.25x	0.51x	6.43x	6.89x	1.89x	1.41x
Quick Ratio	6.13x	6.20x	7.57x	0.25x	0.51x	6.43x	6.89x	1.89x	1.41x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	30K	137K	26.25M	15M	41.65M	28.33M	29.77M	19.14M	31.07M
Long-Term Debt	0	0	13.08M	7.63M	35.85M	24.9M	28.47M	18.96M	31.07M
Capital Lease Obligations	0	0	0	6.75M	5.17M	3.44M	1.3M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	30K	137K	951K	630K	630K	0	0	188K	0
Total Liabilities	4.25M	7.26M	26.25M	51.99M	83.35M	41.27M	38.83M	32.66M	48.68M
Total Debt+	0	0	13.08M	20.75M	48.08M	30.43M	30.1M	18.96M	45.53M
Net Debt	-24.81M	-8.48M	-31.47M	15.92M	33.52M	2.98M	9.01M	12.88M	21.41M
Debt / Equity	-	-	0.18x	-	-	0.61x	1.08x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-179.72x	-118.49x	-2.13x	-4.42x	-12.87x	-	-
Total Equity+	22.67M	39.49M	71.62M	-26.24M	-50.56M	50.23M	28M	-6.4M	-4.08M
Equity Growth %	-	0.74%	0.81%	-1.37%	-0.93%	1.99%	-0.44%	-1.23%	0.36%
Book Value per Share	1.62	71.92	113.40	-24.99	-2.11	4.61	2.29	-0.49	-0.21
Total Shareholders' Equity	22.67M	39.49M	71.62M	-26.24M	-50.56M	50.23M	28M	-6.4M	-4.08M
Common Stock	4K	4K	144K	149K	494K	1.83M	126K	135K	315K
Retained Earnings	-25.33M	-54.74M	-131.79M	-234.92M	-286.93M	-378.49M	-422.93M	-461.3M	-486.07M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-65K	-201K	0	0	0	-350K	1K	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.3M	-30.6M	-75.89M	-81.92M	-54.53M	-15.84M	-18.47M	-39.33M	-26.77M
Operating CF Margin %	-	-60.24%	-87.33%	-2214.11%	-	-	-	-	-
Operating CF Growth %	-	-1.71%	-1.48%	-0.08%	0.33%	0.71%	-0.17%	-1.13%	0.32%
Net Income	-13.46M	-29.41M	-77.06M	-103.13M	-52.01M	-91.56M	-44.43M	-38.37M	-24.77M
Depreciation & Amortization	0	65K	136K	152K	161K	2.1M	1.8M	1.75M	284K
Stock-Based Compensation	348K	392K	1.29M	2.17M	2.76M	4.32M	22.11M	784K	363K
Deferred Taxes	0	44K	-701K	0	1.41M	61.6M	0	0	0
Other Non-Cash Items	-830K	-95K	2.04M	984K	17.71M	8.14M	-258K	-6.26M	10.09M
Working Capital Changes	1.82M	-1.6M	-1.6M	17.9M	-24.56M	-440K	2.31M	2.76M	-12.73M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	1.19M	1.67M	849K	11.45M	-14.67M	63K	1.9M	2.22M	-4.75M
Cash from Investing+	0	-31.59M	-8.66M	40.1M	-11K	-54.59M	13.96M	23.34M	18.21M
Capital Expenditures	0	-812K	-90K	-24K	-11K	-61K	-62K	-13K	-2K
CapEx % of Revenue	-	1.6%	0.1%	0.65%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-30.77K	-8.57K	0	0	-54.53K	0	0	0
Cash from Financing+	20.85M	45.87M	120.84M	2.06M	64.47M	83.13M	-1.82M	1.03M	26.69M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	60K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.3M	-31.42M	-75.98M	-81.95M	-54.54M	-15.9M	-18.54M	-39.34M	-26.77M
FCF Margin %	-	-61.84%	-87.43%	-2214.76%	-	-	-	-	-
FCF Growth %	-	-1.78%	-1.42%	-0.08%	0.33%	0.71%	-0.17%	-1.12%	0.32%
FCF per Share	-0.81	-57.21	-120.30	-78.04	-2.27	-1.46	-1.51	-3.04	-1.36
FCF Conversion (FCF/Net Income)	0.84x	1.04x	0.98x	0.79x	1.05x	0.17x	0.42x	1.02x	1.08x
Interest Paid	0	0	809K	1.4M	996K	416K	22K	0	0
Taxes Paid	130K	439K	352K	414K	120K	435K	821K	401K	220K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.4%	-94.61%	-138.69%	-454.48%	-	-182.28%	-113.59%	-355.35%	-
Return on Invested Capital (ROIC)	-	-153.05%	-161.38%	-512.94%	-	-101.76%	-50.51%	-163.72%	-117.78%
Gross Margin	-	100%	100%	100%	-	-	-	-	-
Net Margin	-	-5788.58%	-8867.2%	-278729.73%	-	-	-	-	-
Debt / Equity	-	-	0.18x	-	-	0.61x	1.08x	-	-
Interest Coverage	-	-	-179.72x	-118.49x	-2.13x	-4.42x	-12.87x	-	-
FCF Conversion	0.84x	1.04x	0.98x	0.79x	1.05x	0.17x	0.42x	1.02x	1.08x
Revenue Growth	-	-	71.06%	-95.74%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Iterum Therapeutics plc (ITRM) reported $0.4M in revenue for fiscal year 2024.

Iterum Therapeutics plc (ITRM) grew revenue by 0.0% over the past year. Growth has been modest.

Iterum Therapeutics plc (ITRM) reported a net loss of $27.0M for fiscal year 2024.

Dividend & Returns

Iterum Therapeutics plc (ITRM) had negative free cash flow of $19.9M in fiscal year 2024, likely due to heavy capital investments.